As the spring wears on and the summer months close in, many people throughout the United States will find themselves dealing with moderate to severe allergies. In this case, these people, including our California readers, will do whatever it takes to find relief.
With many allergy medications on the market, there is no room for those that are defective in any way, shape, or form. Recently, Ranbaxy Laboratories Ltd., a drug maker in India, recalled nearly 30,000 packages of an allergy relief medication that made its way to the United States in February. The U.S. Food and Drug Administration noted that the product was recalled as the result of defective packaging.
The loratadine and pseudoephedrine sulphate packages that have been recalled have an expiration date of September 2015, and came from the company's New Jersey plant.
According to the U.S. Food and Drug Administration, the recall has been classified as Class II. This means that the use of the product could lead to adverse health consequences.
Ranbaxy Laboratories has faced a lot of trouble as of late, with all of its plants in India banned from exporting generic drugs to the United States. This was due to an investigation by the U.S. Food and Drug Administration that turned up quality control issues.
When it comes to the drug industry, companies need to be extremely careful that they do not make any mistakes. One mix up could lead to injuries among those who took the drug, as well as a product liability lawsuit filed by any victims.
Source: Reuters, "Ranbaxy recalls nearly 30,000 packs of allergy-relief drug in U.S" Zeba Siddiqui, May. 02, 2014